Clinical Trials Logo

Clinical Trial Summary

This is a long-term, multicenter, non-interventional study of children ages 2.5 to <17 years with hypochondroplasia (HCH).


Clinical Trial Description

The objective is to evaluate growth, HCH-related medical complications, health-related quality of life, functional abilities and cognitive functions of study participants. Data collected will contribute to the characterization of the natural history of children with HCH. No study medication will be administered. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06410976
Study type Observational
Source QED Therapeutics, Inc.
Contact QED Therapeutics, Inc
Phone 1-877-280-5655
Email medinfo@qedtx.com
Status Recruiting
Phase
Start date June 5, 2024
Completion date October 2026

See also
  Status Clinical Trial Phase
Recruiting NCT05328050 - Registry for Patients With Achondroplasia / Hypochondroplasia (OMPR-Ach/Hy)
Recruiting NCT06212947 - A Multicenter Multinational Observational Study of Children With Hypochondroplasia
Completed NCT01111019 - Efficacy and Safety Evaluation of Recombinant Human Growth Hormone (r-hGH), Saizen®, on a Population of Children With Hypochondroplasia, Treated at Least 3 Years or Until Near Final Height, When Applicable, in Comparison With a Historic Cohort of Non-treated Children Phase 2
Enrolling by invitation NCT06455059 - Interventional Study of Vosoritide for the Treatment of Children With Hypochondroplasia Phase 3
Completed NCT01541306 - C-Type Natriuretic Peptide and Achondroplasia N/A